Abstract P2-05-20: Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype
MV Dieci(University of Padua), Valeria Guarneri(University of Padua), Cristina Ghiotto(Istituto Oncologico Veneto), Giulia Tasca(University of Padua), T Giaratano(University of Padua), PierFranco Conte(University of Padua), Rocco Cappellesso(University of Padua), CA Giorgi(University of Padua), Enrico Orvieto(AULSS 2 Marca Trevigiana), Gaia Griguolo(University of North Carolina at Chapel Hill), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua)
Cited by 3
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290